{
  "source": "PA-Notification-Contraceptives-Medications.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Name 2025 P 1022-12\nProgram Prior Authorization/Notification\nMedication Contraceptive Medications: medroxyprogesterone acetate (Depo-\nProvera®), etonogestrel/ethinyl estradiol (NuvaRing®), Oral\nContraceptives, norelgestromin/ethinyl estradiol (OrthoEvra®), Annovera®\n(segesterone/ethinyl estradiol), Twirla® (levonorgestrel/ethinyl estradiol)\nP&T Approval Date 1/08, 4/09, 10/09, 11/10, 11/2011, 11/2012, 10/2013, 10/2014, 10/2015,\n10/2016, 10/2017, 10/2018, 10/2019, 10/2020, 11/2021, 11/2022, 11/2023,\n3/2025\nEffective Date 6/1/2025\n1. Background:\nThis program is designed for clients who are grandfathered and/or designated a Religious\nExempt organization per the Patient Protection and Affordable Care Act and would like to\nexclude contraceptive products for contraception purposes.\n2. Coverage Criteriaa:\nA. Contraceptive medications will be approved based on the following criterion:\n1. Patient is using the medication for non-contraception purposes. Examples include:\na. Abnormal or excessive bleeding disorders (e.g.-Amenorrhea, oligomenorrhea,\nmenorrhagia, dysfunctional uterine bleeding)\nb. Acne\nc. Decrease in bone mineral density\nd. Dysmenorrhea\ne. Endometriosis\nf. Hirsutism\ng. Irregular menses/cycles\nh. Ovarian cysts\ni. Perimenopausal symptoms\nj. History of Pelvic Inflammatory Disease (PID)\nk. Polycystic Ovarian Syndrome (PCO or PCOS)\nl. Premenstrual Syndrome (PMS)\nm. Premenstrual Dysphoric Disorder (PMDD)\nn. Prevention of endometrial and/or ovarian cancer\no. Prevention of menstrual migraines\np. Turner’s syndrome\nq. Uterine fibroids or adenomyosis\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\n© 2025 UnitedHealthcare Services, Inc.\n1\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHea",
    "overage criteria. Other policies and utilization management\n© 2025 UnitedHealthcare Services, Inc.\n1\nprograms may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. Reference:\nN/A\nProgram Prior Authorization/Notification - Contraceptive Medications\nChange Control\n10/2013 Annual review. No changes to criteria. Added examples of indications\nother than contraception.\n10/2014 Annual review. Increased authorization approval to 60 months.\n10/2015 Annual review. Updated format. Added disclaimer to the background\nsection.\n10/2016 Updated the authorization to 12 months.\n10/2017 Annual review. No changes.\n10/2018 Annual review. No changes.\n10/2019 Annual review. Added Annovera and information on automated approval\nlanguage.\n10/2020 Annual review. Added Twirla.\n11/2021 Annual review. No changes.\n11/2022 Annual review. Added state mandate footnote.\n11/2023 Annual review. No changes.\n3/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}